Targeted therapeutic agents for advanced renal cell carcinoma (RCC) have not significantly improved relative survival rates among patients with the disease, according to a population-based study published online ahead of print in Urologia Internationalis.
In December 2005, FDA approved sorafenib, a targeted agent, for treating advanced RCC. Since then, FDA has approved several targeted agents for treating the disease.
Binay Kumar Shah, MD, of St. Joseph Regional Medical Center in Lewiston, Idaho, and Kishna Bilas Ghimire, MD, of Mercy Medical Center, North Iowa, Mason City, Iowa, analyzed data from the Surveillance, Epidemiology and End Results (SEER) registry database to calculate relative survival rates for patients with advanced RCC. During 2001–2009, the 1- and 3-year relative survival rates were 26.7% and 10%, respectively.
The investigators found no significant difference in 1-year relative survival rates for patients diagnosed during 2006–2007 and 2008–2009 compared with those diagnosed during 2001-2005. The 3-year survival rates for patients diagnosed during 2006–2007 were similar to those diagnosed during 2001–2005.